Glaukos Corporation

Dose Medical Corporation

Allergan, Inc.

Allergan Sales, Inc.

Other

Glaukoa Corporation

David S Haffner

Hosheng Tu

Gregory T Smedley

Thomas W Burns

Barbara A Niksch

Harold Alexander Heitzmann

Kenneth Martin Curry

Charles Raymond Kalina, Jr

Morteza Gharib

Richard A Hill

David Applegate

Olav B Bergheim

John Joseph Cogger

Henrick K Gille

Jason Artof

Chris Calcaterra

Edward Collins

Timothy McCauley

Steven M Henderson

Todd N Fjield

Gary Rangel-Friedman

Patrick Myall

Kenneth E Kadziauskas

Richard L Lindstrom

Kensall D Wise

Bill Evans

Razi-ul M Haque

Nicholas Gunn

Bruce Nogales

Eric Porteous

Douglas Daniel Crimaldi

Morteza (Mory) Gharib

John J Cogger

Dennis M DeCamp

Matt Presta

Cesario Dos Santos

Andrew Johnson

Kenneth M Curry

Terence Arjo

Cesario Pereira Dos Santos

Ken Curry

Charles Raymond Kalina

Razi-Ul M Haque

Timothy Mccauley

Charles Kalina

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Drug eluting ocular implants

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Implants with controlled drug delivery features and methods of using same

Controlled drug delivery ocular implants and methods of using same

Drug eluting ocular implant

Drug eluting ocular implants and methods of treating an ocular disorder

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

System and method for delivering multiple ocular implants

A gonioscopic attachment can attach to a gonioscope and can include atraumatic retention elements that are configured to engage an eye to retain the gonioscope relative to the eye. The gonioscopic attachment can be configured to position the gonioscope so that at least a portion of the concave distal surface of the gonioscopic optical element is spaced apart from the eye, and/or so that the curvature of the distal surface is angularly offset from the curvature of the eye. The gonioscope can include a fixation point configured to be visible to the subject when the gonioscope is positioned on the eye. In some embodiments, the retention elements can be incorporated directly into the gonioscope. A coupling mechanism can couple the gonioscope to a lid speculum. The gonioscope can include a light pipe, which can be configured to directly light into the eye.

Gonioscopic devices

Drug eluting ocular implant and method of treating an ocular disorder

Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Uveoscleral shunt and methods for implanting same

Certain aspects relate to drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye. In several embodiments, the devices are capable of controlled release of two or more drugs, the release of each drug into a different ocular space (e.g., an ocular compartment versus an ocular fluid outflow pathway).

Drug delivery implants with bi-directional delivery capacity

An intraocular pressure (IOP) sensing system may comprise an intraocular pressure sensing implant to be implanted into the eye of a patient for capturing absolute intraocular pressure measurements and an external device for capturing atmospheric pressure measurements. The intraocular pressure sensing implant may be configured to capture an absolute intraocular pressure measurement at an appointed time, and the external device may be configured to capture a plurality of atmospheric pressure measurements around the appointed time.

Intraocular physiological sensor

Growing community of inventors

Mission Viejo, CA, United States of America

David S Haffner